SalMar ASA
22.2.2021 07:26:31 CET | Globenewswire | Press release
SalMar presents results for the fourth quarter 2020 on Thursday 25 February 2021 at 8:00 am CET.
In light of the Covid-19 outbreak and the accompanying disease prevention measures taken into effect by the Norwegian authorities the presentation will be available on Norwegian webcast at 08:00 am CET on www.salmar.no. There will be opportunity to send in questions during the Norwegian presentation. An English webcast (recording) will be available from 10:00 am CET on www.salmar.no.
CEO Gustav Witzøe and CFO & COO Trine Sæther Romuld will be representing the company.
After the presentation two group conferences will be arranged, one in Norwegian at 12:00 am CET and one in English at 14:30 pm CET. For registration please send an email to Carnegie, maria.leidefeldt@carnegie.no.
The results will be available from 6:30 am CET at the company's homepage, www.salmar.no and Oslo Stock Exchange's page, www.newsweb.no.
For more information, please contact:
Håkon Husby, Head of Investor Relations
Tel: +47 936 30 449
Email: hakon.husby@salmar.no
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
King Faisal Specialist Hospital & Research Centre13.3.2026 22:15:53 CET | Press release
KFSH Leads Globally in Paired Kidney Transplants Performed at a Single Center in 2025
SCOR13.3.2026 18:59:39 CET | Press release
SCOR SE announces the availability of its 2025 Universal Registration Document
Novartis Pharma AG13.3.2026 18:35:19 CET | Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Luotea Oyj13.3.2026 18:30:00 CET | Press release
The Board of Directors of Luotea Oyj decided on updates to the company's share-based incentive plan for 2023-2027 and on the launch of a new share-based incentive plan for the years 2026-2030
Ilkka Oyj13.3.2026 18:00:00 CET | Press release
Ilkka Oyj: Acquisition of own shares on 13 March 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
